Retrospective Study Looking at Cinacalcet in the Management of Hyperparathyroidism after Kidney Transplantation. (13th March 2017)

• Record Type: Journal Article
• Authors: Mawad, Habib; Bouchard, Hugues; Tran, Duy; Ouimet, Denis; Lafrance, Jean-Philippe; Bell, Robert Zoël; Bezzaoucha, Sarah; Boucher, Anne; Collette, Suzon; Pichette, Vincent; Senécal, Lynne; Vallée, Michel
• Other Names: Robson Simon C. Academic Editor.
• Is Part Of: Journal of transplantation. Volume 2017(2017)
• Publication Date: 2017-03-13
• Subjects: Transplantation of organs, tissues, etc -- Periodicals; 617.95405
• DOI: 10.1155/2017/8720283
• Languages: English
• ISSNs: 2090-0007

Abstract

Abstract : Objectives. The primary objective of this study is to evaluate the use of cinacalcet in the management of hyperparathyroidism in kidney transplant recipients. The secondary objective is to identify baseline factors that predict cinacalcet use after transplantation. Methods. In this single-center retrospective study, we conducted a chart review of all patients having been transplanted from 2003 to 2012 and having received cinacalcet up to kidney transplantation and/or thereafter. Results. Twenty-seven patients were included with a mean follow-up of2.9 ± 2.4 years. Twenty-one were already taking cinacalcet at the time of transplantation. Cinacalcet was stopped within the first month in 12 of these patients of which 7 had to restart therapy. The main reason for restarting cinacalcet was hypercalcemia. Length of treatment was23 ± 26 months. There were only 3 cases of mild hypocalcemia. There was no statistically significant association between baseline factors and cinacalcet status a year later. Conclusions. Discontinuing cinacalcet within the first month of kidney transplantation often leads to hypercalcemia. Cinacalcet appears to be an effective treatment of hypercalcemic hyperparathyroidism in kidney transplant recipients. Further studies are needed to evaluate safety and long-term benefits.